Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxintong Capsule for Major Adverse Cardiovascular Events in Acute Coronary Syndrome
ChiCTR2000034871Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of naoxintong in acute coronary syndrome (ACS) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Incidence of major adverse cardiovascular events (MACE). Started Jul 2020; status: recruiting.
02
Drugs
naoxintong
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2000034871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034871.